OncoMatch/Clinical Trials/NCT06017583
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Is NCT06017583 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tislelizumab and Capecitabine for rectal neoplasms.
Treatment: Tislelizumab · Capecitabine · Oxaliplatin — This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer. To explore a new PD-1 inhibitor adjuvant chemotherapy model combined with radiotherapy to treat locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Cannot have received: anti-PD-L1 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Cannot have received: anti-CTLA-4 therapy
The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.
Lab requirements
Blood counts
HB≥90g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L
Kidney function
plasma Cr≤1.5 ULN or creatinine clearance ≥60 ml/min
Liver function
TBIL≤1.5 ULN, ALT and AST≤2.5 ULN
blood routine: HB≥90g/L, ANC≥1.5×10^9/L, PLT≥80×10^9/L; Biochemical examination of ALB≥30g/L, TBIL≤1.5 ULN, ALT and AST≤2.5 ULN, plasma Cr≤1.5 ULN or creatinine clearance ≥60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify